Although preclinical models demonstrate that uncommon mutations respond to EGFR‐TKIs to some extent,10, 11 the clinical effectiveness of EGFR‐TKIs in non‐small cell lung cancer (NSCLC) patients with these uncommon mutations remains unclear. This evidence concerns the gene EGFR and non-small cell lung carcinoma.